202 related articles for article (PubMed ID: 36614118)
1. Therapeutic Effect of Rapamycin on TDP-43-Related Pathogenesis in Ischemic Stroke.
Tsou YS; Lai JH; Chen KY; Chang CF; Huang CC
Int J Mol Sci; 2022 Dec; 24(1):. PubMed ID: 36614118
[TBL] [Abstract][Full Text] [Related]
2. Rapamycin alleviates pathogenesis of a new Drosophila model of ALS-TDP.
Cheng CW; Lin MJ; Shen CK
J Neurogenet; 2015; 29(2-3):59-68. PubMed ID: 26219309
[TBL] [Abstract][Full Text] [Related]
3. Autophagy activators rescue and alleviate pathogenesis of a mouse model with proteinopathies of the TAR DNA-binding protein 43.
Wang IF; Guo BS; Liu YC; Wu CC; Yang CH; Tsai KJ; Shen CK
Proc Natl Acad Sci U S A; 2012 Sep; 109(37):15024-9. PubMed ID: 22932872
[TBL] [Abstract][Full Text] [Related]
4. A microfluidic approach to rescue ALS motor neuron degeneration using rapamycin.
Chennampally P; Sayed-Zahid A; Soundararajan P; Sharp J; Cox GA; Collins SD; Smith RL
Sci Rep; 2021 Sep; 11(1):18168. PubMed ID: 34518579
[TBL] [Abstract][Full Text] [Related]
5. Pathological Modification of TDP-43 in Amyotrophic Lateral Sclerosis with SOD1 Mutations.
Jeon GS; Shim YM; Lee DY; Kim JS; Kang M; Ahn SH; Shin JY; Geum D; Hong YH; Sung JJ
Mol Neurobiol; 2019 Mar; 56(3):2007-2021. PubMed ID: 29982983
[TBL] [Abstract][Full Text] [Related]
6. Lower motor neuron involvement in TAR DNA-binding protein of 43 kDa-related frontotemporal lobar degeneration and amyotrophic lateral sclerosis.
Riku Y; Watanabe H; Yoshida M; Tatsumi S; Mimuro M; Iwasaki Y; Katsuno M; Iguchi Y; Masuda M; Senda J; Ishigaki S; Udagawa T; Sobue G
JAMA Neurol; 2014 Feb; 71(2):172-9. PubMed ID: 24378564
[TBL] [Abstract][Full Text] [Related]
7. Functional recovery in new mouse models of ALS/FTLD after clearance of pathological cytoplasmic TDP-43.
Walker AK; Spiller KJ; Ge G; Zheng A; Xu Y; Zhou M; Tripathy K; Kwong LK; Trojanowski JQ; Lee VM
Acta Neuropathol; 2015 Nov; 130(5):643-60. PubMed ID: 26197969
[TBL] [Abstract][Full Text] [Related]
8. The debated toxic role of aggregated TDP-43 in amyotrophic lateral sclerosis: a resolution in sight?
Hergesheimer RC; Chami AA; de Assis DR; Vourc'h P; Andres CR; Corcia P; Lanznaster D; Blasco H
Brain; 2019 May; 142(5):1176-1194. PubMed ID: 30938443
[TBL] [Abstract][Full Text] [Related]
9. The RNA-binding motif 45 (RBM45) protein accumulates in inclusion bodies in amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration with TDP-43 inclusions (FTLD-TDP) patients.
Collins M; Riascos D; Kovalik T; An J; Krupa K; Krupa K; Hood BL; Conrads TP; Renton AE; Traynor BJ; Bowser R
Acta Neuropathol; 2012 Nov; 124(5):717-32. PubMed ID: 22993125
[TBL] [Abstract][Full Text] [Related]
10. ALS and FTLD: two faces of TDP-43 proteinopathy.
Liscic RM; Grinberg LT; Zidar J; Gitcho MA; Cairns NJ
Eur J Neurol; 2008 Aug; 15(8):772-80. PubMed ID: 18684309
[TBL] [Abstract][Full Text] [Related]
11. TDP-43 mutant transgenic mice develop features of ALS and frontotemporal lobar degeneration.
Wegorzewska I; Bell S; Cairns NJ; Miller TM; Baloh RH
Proc Natl Acad Sci U S A; 2009 Nov; 106(44):18809-14. PubMed ID: 19833869
[TBL] [Abstract][Full Text] [Related]
12. Distinct TDP-43 inclusion morphologies in frontotemporal lobar degeneration with and without amyotrophic lateral sclerosis.
Tan RH; Yang Y; Kim WS; Dobson-Stone C; Kwok JB; Kiernan MC; Halliday GM
Acta Neuropathol Commun; 2017 Oct; 5(1):76. PubMed ID: 29078806
[TBL] [Abstract][Full Text] [Related]
13. The pathological phenotypes of human TDP-43 transgenic mouse models are independent of downregulation of mouse Tdp-43.
Xu YF; Prudencio M; Hubbard JM; Tong J; Whitelaw EC; Jansen-West K; Stetler C; Cao X; Song J; Zhang YJ
PLoS One; 2013; 8(7):e69864. PubMed ID: 23922830
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic effect of berberine on TDP-43-related pathogenesis in FTLD and ALS.
Chang CF; Lee YC; Lee KH; Lin HC; Chen CL; Shen CJ; Huang CC
J Biomed Sci; 2016 Oct; 23(1):72. PubMed ID: 27769241
[TBL] [Abstract][Full Text] [Related]
15. [Clinical and pathological spectrum of TDP-43 associated ALS].
Onodera O; Yokoseki A; Tan CF; Ishihara T; Nishiira Y; Toyoshima Y; Kakita A; Nishizawa M; Takahashi H
Rinsho Shinkeigaku; 2010 Nov; 50(11):940-2. PubMed ID: 21921519
[TBL] [Abstract][Full Text] [Related]
16. [FTLD/ALS as TDP-43 proteinopathies].
Ishihara T; Ariizumi Y; Shiga A; Yokoseki A; Sato T; Toyoshima Y; Kakita A; Takahashi H; Nishizawa M; Onodera O
Rinsho Shinkeigaku; 2010 Nov; 50(11):1022-4. PubMed ID: 21921552
[TBL] [Abstract][Full Text] [Related]
17. Phosphorylated and cleaved TDP-43 in ALS, FTLD and other neurodegenerative disorders and in cellular models of TDP-43 proteinopathy.
Arai T; Hasegawa M; Nonoka T; Kametani F; Yamashita M; Hosokawa M; Niizato K; Tsuchiya K; Kobayashi Z; Ikeda K; Yoshida M; Onaya M; Fujishiro H; Akiyama H
Neuropathology; 2010 Apr; 30(2):170-81. PubMed ID: 20102522
[TBL] [Abstract][Full Text] [Related]
18. Expression of TDP-43 C-terminal Fragments in Vitro Recapitulates Pathological Features of TDP-43 Proteinopathies.
Igaz LM; Kwong LK; Chen-Plotkin A; Winton MJ; Unger TL; Xu Y; Neumann M; Trojanowski JQ; Lee VM
J Biol Chem; 2009 Mar; 284(13):8516-24. PubMed ID: 19164285
[TBL] [Abstract][Full Text] [Related]
19. Drosophila TDP-43 dysfunction in glia and muscle cells cause cytological and behavioural phenotypes that characterize ALS and FTLD.
Diaper DC; Adachi Y; Lazarou L; Greenstein M; Simoes FA; Di Domenico A; Solomon DA; Lowe S; Alsubaie R; Cheng D; Buckley S; Humphrey DM; Shaw CE; Hirth F
Hum Mol Genet; 2013 Oct; 22(19):3883-93. PubMed ID: 23727833
[TBL] [Abstract][Full Text] [Related]
20. Znf179 E3 ligase-mediated TDP-43 polyubiquitination is involved in TDP-43- ubiquitinated inclusions (UBI) (+)-related neurodegenerative pathology.
Lee YC; Huang WC; Lin JH; Kao TJ; Lin HC; Lee KH; Lin HC; Shen CJ; Chang WC; Huang CC
J Biomed Sci; 2018 Nov; 25(1):76. PubMed ID: 30404641
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
